Literature DB >> 20850732

Enough is enough! Patients who do not conceive on 600 IU/d of gonadotropins show no improvement from an additional 150 IU of LH activity.

Marcy Maguire1, John Csokmay, James Segars, Mark Payson, Alicia Armstrong.   

Abstract

Studies have suggested that supplemental LH improves outcomes in assisted reproductive technology (ART) cycles. In this retrospective review, an additional 150 IU of LH activity did not improve ART outcomes in women undergoing a second round of IVF/ intracytoplasmic sperm injection (ICSI) after an initial failed cycle using 600 IU of gonadotropins. Published by Elsevier Inc.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20850732      PMCID： PMC3005079          DOI： 10.1016/j.fertnstert.2010.08.020

Source DB:  PubMed          Journal:  Fertil Steril        ISSN： 0015-0282            Impact factor:   7.329


  8 in total

Review 1.  Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles.

Authors:  M H Mochtar; M Ziech; M van Wely
Journal:  Cochrane Database Syst Rev       Date:  2007-04-18

2.  A randomized prospective assessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome.

Authors:  U D Gordon; R F Harrison; M Fawzy; B Hennelly; A C Gordon
Journal:  Fertil Steril       Date:  2001-02       Impact factor: 7.329

3.  The limited importance of pronuclear scoring of human zygotes.

Authors:  Aidita N James; Sasha Hennessy; Brett Reggio; Klaus Wiemer; Frederick Larsen; Jacques Cohen
Journal:  Hum Reprod       Date:  2006-02-17       Impact factor: 6.918

Review 4.  What should be the maximum FSH dose in IVF/ICSI in poor responders?

Authors:  C S Siristatidis; M P Hamilton
Journal:  J Obstet Gynaecol       Date:  2007-05       Impact factor: 1.246

5.  Ovarian responses in women to recombinant follicle-stimulating hormone and luteinizing hormone (LH): a role for LH in the final stages of follicular maturation.

Authors:  M W Sullivan; A Stewart-Akers; J S Krasnow; S L Berga; A J Zeleznik
Journal:  J Clin Endocrinol Metab       Date:  1999-01       Impact factor: 5.958

6.  What is the optimum maximal gonadotropin dosage used in microdose flare-up cycles in poor responders?

Authors:  Murat Berkkanoglu; Kemal Ozgur
Journal:  Fertil Steril       Date:  2009-04-14       Impact factor: 7.329

Review 7.  Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis.

Authors:  E M Kolibianakis; L Kalogeropoulou; G Griesinger; E G Papanikolaou; J Papadimas; J Bontis; B C Tarlatzis
Journal:  Hum Reprod Update       Date:  2007-06-23       Impact factor: 15.610

Review 8.  Clinical management of low ovarian response to stimulation for IVF: a systematic review.

Authors:  B C Tarlatzis; L Zepiridis; G Grimbizis; J Bontis
Journal:  Hum Reprod Update       Date:  2003 Jan-Feb       Impact factor: 15.610
  8 in total
  3 in total

1.  Outcome of in vitro fertilization in patients with proven poor ovarian responsiveness after early vs. mid-follicular LH exposure: a prospective, randomized, controlled study.

Authors:  Alberto Revelli; Alessandra Chiado'; Daniela Guidetti; Francesca Bongioanni; Valentina Rovei; Gianluca Gennarelli
Journal:  J Assist Reprod Genet       Date:  2012-05-29       Impact factor: 3.412

2.  Controlled Ovarian Stimulation with recombinant-FSH plus recombinant-LH vs. human Menopausal Gonadotropin based on the number of retrieved oocytes: results from a routine clinical practice in a real-life population.

Authors:  Alberto Revelli; Grazia Pettinau; Gemma Basso; Andrea Carosso; Alessandro Ferrero; Cecilia Dallan; Stefano Canosa; Gianluca Gennarelli; Daniela Guidetti; Claudia Filippini; Chiara Benedetto
Journal:  Reprod Biol Endocrinol       Date:  2015-07-25       Impact factor: 5.211

3.  Controlled ovarian stimulation with r-FSH plus r-LH vs. HMG plus r-FSH in patients candidate for IVF/ICSI cycles: An RCT.

Authors:  Ensieh Shahrokh Tehraninejad; Mina Farshbaf Taghinejad; Batool Hossein Rashidi; Fedyeh Haghollahi
Journal:  Int J Reprod Biomed       Date:  2017-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.